Majid Al Othman, Unit Head of Radiation Oncology at Johns Hopkins Aramco Healthcare (JHAH), shared a post on LinkedIn about a recent article by Yoshinori Imamura et al, published on Cancer Treatment Reviews:
“NIVOPOST-OP trial (presented in ASCO 25) is a new option for high-risk HEAD and NECK after surgery adding Nivo to adjuvant CRT.
Compare to the breakthrough Keynote 689 (NEJM June 25) with perioperative Pembro.”
Title: Comparative review of KEYNOTE-689 and NIVOPOSTOP trials and their impact on perioperative immunotherapy in locally advanced head and neck cancer
Authors: Yoshinori Imamura, Masafumi Kanno, Shigeharu Fujieda
Read the full article on Cancer Treatment Reviews.
More posts featuring Majid Al Othman on OncoDaily.
